INTRODUCTION
Retinopathy of prematurity (ROP) is a multifactorial, vasoproliferative disease which is the leading cause of preventable childhood blindness, both in developing and developed countries. The difference in incidence and risk factors (1) is made according to the degree of the development of health care system (perinatal care, screening criteria) and race (2) (3) (4) (5) (6) . World Health Organization gave great significance to ROP control by introducing the protocol for following up prematurely born children -'Vision 2020 Programme' (7) . Anti VEGF therapy is good choice with great effects for the treatment of the active form of ROP.
PATHOGENESIS
ROP is a biphasic disease. In the first phase hyperoxy and obliteration of blood vessels can be detected. The second is presented with hypoxia and neovascularization (8, 9) . Retinal vascularization starts in the 16th week of gestation and finishes soon after birth. The birth of the child means the transitions in relative hyperoxic environment with possibly added oxygen. Hyperoxigen conditions make the developing of the obliteration and the discontinuation of the already developed retinal blood vessels. That is the first ROP phase that lasts from birth till the 30 th -31 st week of gestation (9) . Further retinal development demands more oxygen because of its increased growth and metabolic processes. Immature, ischemic retinal zones become more hypoxic and stimulate the hyper production of vascular endothelial growth factor (VEGF), which results in the abnormal retinal neovascularization. That is the second ROP phase that starts from the 31 st -32 nd week of gestation (10, 11) . In that phase the insulin-like growth factor (IGF) has a prominent role. Its secretion is in tight conjunction with the gestational age and newborn`s weight. VEGF and IGF are synergists. IGF has a role in the process of normal vascularization.
Also, it regulates retinal neovascularization by controlling VEGF activation regardless of oxygenation (11) . Low serum level of IGF stops blood vessels development, and it is the predictor of ROP (12, 13 other tissues` condition-liver, the uterus, the placenta. Its low serum level can be the indicator of a sick child even without the ROP risk (14) .
CLASSIFICATION
International Classification of Retinopathy of Prematurity (ICROP) used: presenting zone, intensity of ROP and stage (15) .
Severeness of the ROP changes is determined in relation to (Figure 1) 1. Localization a) 1 st zone that includes optic disc (PNO), with radius of two PNO-macula lengths b) 2 nd zone includes the area till ora serrata nasally c) 3 rd zone radius includes the area till the ora serrata temporally 2. Expansion presents changes determined by the portion of the affected retina in relation to the clock hours 3. Stages a) stage 1 refers to the demarcation line that represents the first pathognomonic sign of ROP b) stage 2 is represented by the reef c) stage 3 is the reef with extraretinal fibrovascular proliferation d) stage 4 represents subtotal retinal ablation with or without infecting the macula e) stage 5 is represented by the total retinal ablation 4. 'Plus' disease -the impossibility of the dilation of the pupil with the expanded blood vessels of the iris, blurred vitreous visualization, venous dilatation and arterial tortuosity at fundus, and preretinal and vitreous hemorrhage (16) .
Screening is performed in the cases of highly risked prematures of a younger gestational age at birth, small body weight at birth, or those that were exposed to oxygen with a partial pressure higher than 1% for a longer period of time in special units of pediatric clinics. Controls are conducted till retinal vascularization is finished. Screening process is performed in mydriasis, 4-6 weeks after birth, when ROP condition is determined. This fundus finding determine control rhythm and urgency as well as the need for treatment. In reference to that, the disease according to the degree of urgency is divided into three groups: 
MODALITIES OF THE ROP TREATMENT
The laser photocoagulation of the avascular retina, whether the laser photocoagulation (argon or diode laser) or cryotherapy, still remains the gold standard for ROP treatment from the 1 st to the 3 rd stage and for the aggressive posterior retinopathy forms (18) . This treatment must be performed by competent ophthalmologist in topical anesthesia with transpupillary or trans-scleral approach. Subsequent to application, an early complete regression of extraretinal proliferation is observed (19) . Some other complications have been reported, such as: the early ones -corneal edema, intraocular hemorrhage, ocular hypertension and the late ones -significant narrowing of peripheral vision as a consequence of retinal cells necrosis, high degree myopia, glaucoma, retinal detachment, strabismus. Despite of all the above mentioned, the only approved ROP therapy is the laser photocoagulation combined with vitreoretinal surgery (scleral buckling or pars plana vitrectomy), depending on the severity of the disease.
There are also several new therapeutic modalities for ROP treatment, such as anti-VEGF (20) (21) (22) (23) (24) (25) , systemic propranolol (26, 27) , gene therapy (28), IGF (29) , dietary supplementation with omega-3 fatty acids and vitamin E (30,31).
ANTI-VEGF THERAPY
VEGF is a potent mitogen for vascular endothelial cells, whose secretion depends on the tissue hypoxia (10), for physiological and pathological angiogenesis. The aim of anti-VEGF therapy is to block the effect of VEGF on pathological retinal vascularization, but without the destruction of tissues of retina and the vitreus. It is applied in clinical conditions, in local anesthesia. The amount of 0.1 ml of drug is applied 4 mm from the limbus under the control of the magnifier of 20D strength. Currently available medicines are ranibizumab (®Lucentis), bevacizumab (®Avastin), pegaptanib natrium (®Macugen) and aflibercept (®Eylea). FDA approved ranibizumab, pegaptanib natrium and aflibercept for intraocular application in adults (32) . The first approved medicine for the treatment of senile macular degeneration is pegaptanib natrium. However, there are several described cases in which intravitreal application of pegaptanib at the ROP stage 3+ led to successful results without any systemic or ocular complications during the following period of 19 months (33) . Ranibizumab has a shorter half-life in the serum than bevacizumab, so theoretically it probably causes less undesirable systemic effects in new born children. The aflibercept has a longer half-life than all anti-VEGF medicines. The number of described cases with intravitreal anti-VEGF application is constantly increasing in the literature. Lee et al. described great benefit of anti VEGF intravitreal applied as regression of neovascularization and the continuation of a normal vascularization, without the appearance of complications or the reactivation of the disease within the period of 3 years during which the children were followed up (24) . Other data suggested that anti VEGF intravitreal applied may cause systemic complications because of the known VEGF influence for the physiological development of the brain, the lungs, the kidneys (34) . In addition, the following systemic complications were observed: hypertension, a transient ischemic attack, pulmonary hypertension, tromboemboly, cerebrovascular insult and death (35) . The reported local complications are endophthalmitis, retinal ruptures, a severe uveitis, intraocular hypertension, glaucoma, cataract (35) . using of anti VEGF as monotherapy or additional therapy is the matter of local findings and the choice of ophthalmologist (36) .
PROPRANOLOL
Propranolol applied systemicaly decrease the level of the VEGf, which can be useful in the ROP treatment (37) . Prospective studies in which the new born children were treated with propranolol per os, showed that 48% of them decreased the risk of the third stage development, 58 % of them decreased the progression into stage 3+, and 100% decreased the progression into the 4th stage (37). However, propranolol has serious undesirable effects such as bradycardia, branch block, hypotension, bronchospasm, hypoglycemia, dyslipidemia (38) , which can be very harmful in prematures. Therefore, before the propranolol application, the usefulness and safety for every individual case should be considered. Additionally, it is necessary to mention that the effect of propranolol has still to be examined.
GENE THERAPY
Gene therapy influences numerous cytokines and growth factors activity, that are known to participate in the ROP pathogenesis. It is considered to be included in the therapy of ROP. Chowers et al showed its efficacy in the ROP regression in rat model (39) , but the safety of the gene therapy application in prematures and its possible effects on a child's development are uncertain and should be completely evaluated (40) .
THE ADDITIONAL THERAPY
1. Omega-3 polyunsaturated fatty acids transmit through placenta from the mother to baby, in the third trimester of pregnancy. This phenomenon does not occur in prematures. In the conducted study on the mice with ROP, the application of omega-3 polyunsaturated fatty acids showed in the 50% of cases a protective effect against a pathological neovascularization (41), but it is necessary to conduct more clinical trials to confirm the safety of the application in prematures.
2. Based on reachable data, erythropoietin is angiogenic growth factor depending on the oxygen concentration, with the effects similar to VEGF (42) . However, the role of erythropoietin in the normal human retinal vasculogenesis has not been known yet (42) .
3. IGF-1 is the oxygen-independent growth factor important for normal retinal vascularization. It acts by regulating the VEGF signalization. Its level increases mostly in the third pregnancy trimester and decreases sharply after birth. This fact can be explained by its production in placenta and fetal liver. In prematures, low IGF level is associated with the discontinuation of vascularization and the development of ROP (16, 17) . By using a IGF-1 receptor antagonist, neovascularization is suppressed and normal retinal vasculogenesis continues (43), but there are no studies that confirm its safe application in prematures.
4. Granulocyte colony-stimulating factor (GCSF) is a biological cytokine that increases the IGF-1 level, which supports normal vasculogenesis. In that way GCSF promotes angiogenesis in the ischemic retina without any negative effects on VEGF (44).
5. Vitamin E. Antioxidative system is functionally immature in prematures that are susceptible to oxidative stress and the development of the disease connected to the oxygen concentration such as ROP. Nevertheless, the results of meta-analysis of random studies with the supplementation of vitamin E are contradictory: vitamin E supplementation didn't lead to the decrease of the risk for ROP, even the risk for sepsis development and necrotizing enterocolitis is increased (45) .
CONCLUSION
The frequency of ROP is different in numerous studies, but the progress of neonatal intensive care and the increased survival of prematurely born children have led to the increased rate of ROP that demands screening and treatment (1) (2) (3) (4) (5) (6) (7) (8) . The prevention of the development of the severe ROP forms is the best strategy at the moment in order to avoid the damage of visual function, even blindness. Current gold standard treatment for a proliferative ROP is the panretinal laser photocoagulation, but it's not ideal due to the damage of peripheral vision and possible high degree myopia. However, countless studies have been conducted that examine the safety and efficiency of antiangiogenic therapy, anti-VEGF in the first place, in prematures. The results of those studies are encouraging and valuable for the new ROP therapeutic modules in the near future.
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